Rosalind Advisors Inc. Sells 641,577 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Rosalind Advisors Inc. lowered its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 46.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 750,000 shares of the company's stock after selling 641,577 shares during the period. Trevi Therapeutics accounts for about 1.6% of Rosalind Advisors Inc.'s investment portfolio, making the stock its 16th largest holding. Rosalind Advisors Inc. owned about 1.03% of Trevi Therapeutics worth $2,505,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in TRVI. Ally Bridge Group NY LLC bought a new position in Trevi Therapeutics in the second quarter worth $4,395,000. Logos Global Management LP increased its stake in shares of Trevi Therapeutics by 27.3% in the 2nd quarter. Logos Global Management LP now owns 2,800,000 shares of the company's stock worth $8,344,000 after acquiring an additional 600,000 shares in the last quarter. Propel Bio Management LLC purchased a new position in Trevi Therapeutics during the 1st quarter valued at about $897,000. Opaleye Management Inc. boosted its stake in Trevi Therapeutics by 4.3% during the first quarter. Opaleye Management Inc. now owns 2,645,000 shares of the company's stock worth $9,125,000 after acquiring an additional 110,000 shares in the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new stake in Trevi Therapeutics in the first quarter worth about $208,000. Hedge funds and other institutional investors own 95.76% of the company's stock.

Trevi Therapeutics Stock Up 2.6 %

TRVI traded up $0.08 during midday trading on Wednesday, hitting $3.10. 474,271 shares of the company traded hands, compared to its average volume of 281,646. The company's 50-day moving average is $3.15 and its 200 day moving average is $2.91. The firm has a market capitalization of $225.03 million, a PE ratio of -7.95 and a beta of 1.01. Trevi Therapeutics, Inc. has a 52 week low of $0.97 and a 52 week high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.01). During the same period last year, the company earned ($0.07) EPS. On average, sell-side analysts predict that Trevi Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Trevi Therapeutics

In other news, CEO Jennifer L. Good sold 10,981 shares of the company's stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the sale, the chief executive officer now owns 213,313 shares of the company's stock, valued at $644,205.26. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Trevi Therapeutics news, insider Thomas Sciascia sold 18,660 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.76, for a total value of $51,501.60. Following the completion of the sale, the insider now owns 220,315 shares in the company, valued at approximately $608,069.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jennifer L. Good sold 10,981 shares of the business's stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the transaction, the chief executive officer now owns 213,313 shares in the company, valued at $644,205.26. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,355 shares of company stock valued at $116,663. 24.37% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Leerink Partners began coverage on Trevi Therapeutics in a research report on Monday, September 9th. They issued an "outperform" rating and a $7.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $6.00 target price on shares of Trevi Therapeutics in a report on Tuesday, October 22nd. B. Riley restated a "buy" rating and set a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. Leerink Partnrs upgraded shares of Trevi Therapeutics to a "strong-buy" rating in a research note on Monday, September 9th. Finally, EF Hutton Acquisition Co. I upgraded shares of Trevi Therapeutics to a "strong-buy" rating in a research note on Monday, August 19th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Trevi Therapeutics currently has an average rating of "Buy" and an average price target of $7.43.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.